Anti-Human Thymic Stromal Lymphopoietin (TSLP) (Tezepelumab)

Unknown

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tezepelumab. MEDI9929 (Tezepelumab; AMG157) activity is directed against human TSLP.

Thymic stromal lymphopoietin (TSLP) is a pleiotropic, epithelium-derived cytokine that is characterized as a lymphocyte growth factor¹. TSLP plays a key role in the inflammatory response of the lung, such as in asthma and COPD pathobiology. To function, TSLP engages a heteromeric complex of TSLP receptor chain and interleukin 7 receptor-α (IL-7Rα) to induce STAT5. TSLP can be expressed as either a long or short isoform. It is the long isoform that is specifically upregulated by inflammatory stimuli in human bronchial epithelial cells and macrophages. In contrast, the short isoform is constitutively expressed in bronchial and colonic epithelial cells, lung fibroblasts, macrophages, and keratinocytes. TSLP mediates airway structural cell and immune cell interactions 2 . TSLP activity is upstream of the asthma inflammatory cycle making it an effective target for treatment.

MEDI9929 (Tezepelumab) is a fully human monoclonal antibody developed for the treatment of asthma, COPD, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and eosinophilic esophagitis². Tezepelumab inhibits the action of TSLP by blocking interaction with its receptor TSLPR. Tezepelumab reduces T2 inflammatory biomarkers, including airway eosinophil counts, when administered in vivo^3,4,5.

TSLP is mainly expressed by bronchial epithelial cells. TSLP also selectively localizes to the cytoplasm of human lung macrophages (HLM) and can be released by HLMs. Additionally, TSLP is expressed by human dendritic cells, airway smooth muscle cells, mast cells, monocytes, granulocytes, and fibroblasts.

TSLP receptor (TSLPR) chain and interleukin 7 receptor-α

1 Canè L, Poto R, Palestra F, et al. Eur J Intern Med. 124:89-98. 2024.
2 Hoy SM. Drugs. 82(4):461-468. 2022.
3 Gauvreau GM, O'Byrne PM, Boulet LP, et al. N Engl J Med. 370(22):2102-2110. 2014.
4 Diver S, Khalfaoui L, Emson C, et al. Lancet Respir Med. 9(11):1299-1312. 2021.
5 Corren J, Pham TH, Garcia Gil E, et al. Allergy. 77(6):1786-1796. 2022.
6 Zheng Y, Abuqayyas L, Megally A, et al. Clin Ther. 43(1):142-155.e5. 2021.